Loading...

Calithera Biosciences

DB:2CB
Snowflake Description

Flawless balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2CB
DB
$239M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
  • Calithera Biosciences has significant price volatility in the past 3 months.
2CB Share Price and Events
7 Day Returns
-7.3%
DB:2CB
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
7.5%
DB:2CB
-9.2%
DE Biotechs
-6.7%
DE Market
2CB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Calithera Biosciences (2CB) -7.3% -7.2% 34.1% 7.5% 7.5% -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 2CB outperformed the Biotechs industry which returned -9.2% over the past year.
  • 2CB outperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
2CB
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Calithera Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Calithera Biosciences to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Calithera Biosciences.

DB:2CB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:2CB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:2CB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Calithera Biosciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:2CB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 -55.70 Analyst x1 -51.57
2020 -61.40 Analyst x1 -52.63
2021 26.70 Analyst x1 21.19
2022 27.30 Analyst x1 20.06
2023 32.90 Analyst x1 22.38
2024 37.21 Est @ 13.1% 23.44
2025 40.65 Est @ 9.24% 23.70
2026 43.30 Est @ 6.54% 23.38
2027 45.31 Est @ 4.64% 22.65
2028 46.82 Est @ 3.32% 21.67
Present value of next 10 years cash flows $74.27
DB:2CB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $46.82 × (1 + 0.23%) ÷ (8.01% – 0.23%)
$603.08
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $603.08 ÷ (1 + 8.01%)10
$279.11
DB:2CB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $74.27 + $279.11
$353.38
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $353.38 / 39.16
$9.02
DB:2CB Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:2CB represents 0.86201x of NasdaqGS:CALA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86201x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 9.02 x 0.86201
€7.78
Value per share (EUR) From above. €7.78
Current discount Discount to share price of €5.31
= -1 x (€5.31 - €7.78) / €7.78
31.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Calithera Biosciences is available for.
Intrinsic value
32%
Share price is €5.31 vs Future cash flow value of €7.78
Current Discount Checks
For Calithera Biosciences to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Calithera Biosciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Calithera Biosciences's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Calithera Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Calithera Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2CB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.49
NasdaqGS:CALA Share Price ** NasdaqGS (2019-04-18) in USD $6.16
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Calithera Biosciences.

DB:2CB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CALA Share Price ÷ EPS (both in USD)

= 6.16 ÷ -1.49

-4.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Calithera Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Calithera Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Calithera Biosciences's expected growth come at a high price?
Raw Data
DB:2CB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
1.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Calithera Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Calithera Biosciences's assets?
Raw Data
DB:2CB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.26
NasdaqGS:CALA Share Price * NasdaqGS (2019-04-18) in USD $6.16
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:2CB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CALA Share Price ÷ Book Value per Share (both in USD)

= 6.16 ÷ 3.26

1.89x

* Primary Listing of Calithera Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Calithera Biosciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Calithera Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Calithera Biosciences has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Calithera Biosciences expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
1.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Calithera Biosciences expected to grow at an attractive rate?
  • Unable to compare Calithera Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Calithera Biosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Calithera Biosciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2CB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2CB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 1.5%
DB:2CB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 44.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2CB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2CB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 33
2022-12-31 174 28 -7 1
2021-12-31 20 27 -125 1
2020-12-31 26 -61 -91 2
2019-12-31 26 -55 -77 2
DB:2CB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 22 -65 -55
2018-09-30 30 -62 -46
2018-06-30 37 -57 -33
2018-03-31 27 -36 -35
2017-12-31 26 14 -28
2017-09-30 19 16 -26
2017-06-30 11 21 -29
2017-03-31 4 12 -34
2016-12-31 -31 -38
2016-09-30 -32 -37
2016-06-30 -32 -37
2016-03-31 -30 -34

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Calithera Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Calithera Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2CB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Calithera Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2CB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 -0.15 -0.15 -0.15 1.00
2021-12-31 -2.51 -2.51 -2.51 1.00
2020-12-31 -1.78 -1.47 -2.40 3.00
2019-12-31 -1.82 -1.48 -2.36 3.00
DB:2CB Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.49
2018-09-30 -1.28
2018-06-30 -0.93
2018-03-31 -1.00
2017-12-31 -0.84
2017-09-30 -0.90
2017-06-30 -1.14
2017-03-31 -1.60
2016-12-31 -1.95
2016-09-30 -1.95
2016-06-30 -2.00
2016-03-31 -1.89

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Calithera Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Calithera Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Calithera Biosciences has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Calithera Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Calithera Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Calithera Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Calithera Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Calithera Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Calithera Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Calithera Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2CB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 22.25 -54.63 13.34
2018-09-30 29.51 -46.10 13.39
2018-06-30 36.76 -33.33 13.38
2018-03-31 26.95 -35.45 12.73
2017-12-31 25.96 -27.83 12.53
2017-09-30 18.70 -26.37 11.94
2017-06-30 11.45 -28.85 11.19
2017-03-31 4.19 -34.01 11.00
2016-12-31 -38.00 10.59
2016-09-30 -36.55 9.87 5.83
2016-06-30 -36.91 9.75 12.59
2016-03-31 -34.37 9.43 18.12
2015-12-31 -32.64 9.07
2015-09-30 -31.41 8.64 22.89
2015-06-30 -27.75 7.79 20.03
2015-03-31 -25.42 6.76 18.68
2014-12-31 -21.71 5.35 16.37
2014-09-30 -18.97 4.48 14.49
2014-06-30 -17.05 3.72 13.33
2014-03-31 -14.04 2.86 11.18
2013-12-31 -12.38 2.48 9.90
2012-12-31 -5.09 1.42 6.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Calithera Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Calithera Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Calithera Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Calithera Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Calithera Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Calithera Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Calithera Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Calithera Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Calithera Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Calithera Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Calithera Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Calithera Biosciences Company Filings, last reported 3 months ago.

DB:2CB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 126.71 0.00 136.15
2018-09-30 135.91 0.00 141.46
2018-06-30 147.17 0.00 141.41
2018-03-31 147.87 0.00 150.96
2017-12-31 150.31 0.00 163.79
2017-09-30 158.09 0.00 165.61
2017-06-30 162.46 0.00 166.23
2017-03-31 165.73 0.00 155.33
2016-12-31 49.91 0.00 51.78
2016-09-30 53.81 0.00 56.27
2016-06-30 58.22 0.00 60.38
2016-03-31 67.27 0.00 66.19
2015-12-31 71.79 0.00 69.93
2015-09-30 78.60 0.00 81.89
2015-06-30 86.32 0.00 77.70
2015-03-31 93.10 0.00 88.58
2014-12-31 100.37 0.00 101.97
2014-09-30 35.23 0.00 34.85
2014-06-30 24.24 0.00 27.75
2014-03-31 33.47 0.00 33.82
2013-12-31 33.47 0.00 33.82
2012-12-31 2.15 0.00 2.21
  • Calithera Biosciences has no debt.
  • Calithera Biosciences has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Calithera Biosciences has sufficient cash runway for 2.1 years based on current free cash flow.
  • Calithera Biosciences has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 25.9% each year.
X
Financial health checks
We assess Calithera Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Calithera Biosciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Calithera Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Calithera Biosciences dividends. Estimated to be 0% next year.
If you bought €2,000 of Calithera Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Calithera Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Calithera Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2CB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2CB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Calithera Biosciences has not reported any payouts.
  • Unable to verify if Calithera Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Calithera Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Calithera Biosciences has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Calithera Biosciences's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Calithera Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Calithera Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Calithera Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Calithera Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Susan Molineaux
COMPENSATION $760,939
AGE 64
TENURE AS CEO 9.1 years
CEO Bio

Dr. Susan M. Molineaux, Ph.D., Co-founded Calithera Biosciences, Inc. in June 2010 and has been its Chief Executive Officer and President since June 2010. Dr. Molineaux also serves as Principal Financial Officer of Calithera Biosciences, Inc. Dr. Molineaux Co-founded Proteolix, Inc. (now known as Onyx Therapeutics, Inc.) in December 2003, where she served as Chief Scientific Officer from December 2003 to December 2005, Chief Executive Officer from January 2006 to January 2009 and again as Chief Scientific Officer from February 2009 until Proteolix's acquisition by Onyx Pharmaceuticals, Inc. in November 2009. She served as President of Proteolix, Inc. Prior to joining Proteolix, Inc., Dr. Molineaux was at Rigel Pharmaceuticals Inc. in South San Francisco, CA from 2000 to 2003, where she served as Vice President of Biology and Senior Director. Prior to that, she served as Vice President of Biology at Praelux in Lawrenceville, NJ from 1999 to 2000. From 1994 to 1999, Dr. Molineaux served as Vice President of Drug Development at Praecis Pharmaceuticals in Cambridge, MA and from 1989 to 1994, she was a Scientist in the Immunology group at Merck, in Rahway, NJ. She serves as Director of BayBio. She has been an Independent Director of Geron Corporation since September 26, 2012 and Theravance Biopharma, Inc. since April 22, 2015. She has been a Director of Calithera Biosciences, Inc. since March 2010. She is Scientific Advisor to Lightstone Ventures since September 2016. She served as Director of Proteolix Inc. She serves as a member of the board of directors of We Teach Science and served as California Life Sciences Association until March 2016. She served as Director of Bay Area Bioscience Association. Dr. Molineaux received a BS in Biology from Smith College, a Ph.D. in Molecular Biology from Johns Hopkins University and completed a postdoctoral fellowship at Columbia University.

CEO Compensation
  • Susan's compensation has been consistent with company performance over the past year.
  • Susan's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Calithera Biosciences management team in years:

2.6
Average Tenure
47
Average Age
  • The tenure for the Calithera Biosciences management team is about average.
Management Team

Susan Molineaux

TITLE
Co-Founder
COMPENSATION
$761K
AGE
64
TENURE
9.1 yrs

Sumita Ray

TITLE
Senior VP
COMPENSATION
$1M
AGE
44
TENURE
1.5 yrs

Keith Orford

TITLE
Chief Medical Officer
COMPENSATION
$649K
AGE
46
TENURE
2.9 yrs

Stephanie Wong

TITLE
Senior VP of Finance & Secretary
AGE
44

Jennifer McNealey

TITLE
Vice President of Investor Relations & Strategy
TENURE
2.3 yrs

Hagit Glickman

TITLE
Head of People & Culture

Eric Sjogren

TITLE
Senior Vice President of Drug Discovery
COMPENSATION
$960K
AGE
61
TENURE
8.8 yrs

Christopher Molineaux

TITLE
Senior Vice President of Development
COMPENSATION
$447K
AGE
65
TENURE
6 yrs

Curtis Hecht

TITLE
Chief Business Officer
AGE
47
TENURE
0.3 yrs

Sam Whiting

TITLE
Senior Vice President of Clinical Development
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Calithera Biosciences board of directors in years:

4
Average Tenure
54.5
Average Age
  • The tenure for the Calithera Biosciences board of directors is about average.
Board of Directors

Susan Molineaux

TITLE
Co-Founder
COMPENSATION
$761K
AGE
64
TENURE
9.1 yrs

Jean George

TITLE
Director
COMPENSATION
$162K
AGE
60
TENURE
6.6 yrs

Deepa Pakianathan

TITLE
Lead Independent Director
COMPENSATION
$185K
AGE
53
TENURE
2.3 yrs

H. Wolff

TITLE
Director
COMPENSATION
$163K
AGE
69
TENURE
4.3 yrs

John Drachman

TITLE
Director
COMPENSATION
$153K
AGE
56
TENURE
5.3 yrs

Sunil Agarwal

TITLE
Independent Director
COMPENSATION
$159K
AGE
48
TENURE
3.6 yrs

Suzy Jones

TITLE
Director
COMPENSATION
$156K
AGE
52
TENURE
2.7 yrs

Blake Wise

TITLE
Director
COMPENSATION
$271K
AGE
47
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Calithera Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Calithera Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience’s portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Details
Name: Calithera Biosciences, Inc.
2CB
Exchange: DB
Founded: 2010
$212,484,467
39,156,384
Website: http://www.calithera.com
Address: Calithera Biosciences, Inc.
343 Oyster Point Boulevard,
Suite 200,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CALA Common Stock Nasdaq Global Select US USD 03. Oct 2014
DB 2CB Common Stock Deutsche Boerse AG DE EUR 03. Oct 2014
Number of employees
Current staff
Staff numbers
79
Calithera Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:14
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/26
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.